- Home
- GHRS vs PHAT Comparison
GHRS vs PHAT Comparison
Compare GHRS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- PHAT
- Stock Information
- Founded
- GHRS 2018
- PHAT 2018
- Country
- GHRS Ireland
- PHAT United States
- Employees
- GHRS N/A
- PHAT N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- PHAT Health Care
- Exchange
- GHRS Nasdaq
- PHAT Nasdaq
- Market Cap
- GHRS 774.1M
- PHAT 820.8M
- IPO Year
- GHRS 2021
- PHAT 2019
- Fundamental
- Price
- GHRS $11.94
- PHAT $11.84
- Analyst Decision
- GHRS Strong Buy
- PHAT Strong Buy
- Analyst Count
- GHRS 8
- PHAT 5
- Target Price
- GHRS $30.63
- PHAT $16.40
- AVG Volume (30 Days)
- GHRS 190.5K
- PHAT 1.1M
- Earning Date
- GHRS 11-13-2025
- PHAT 11-06-2025
- Dividend Yield
- GHRS N/A
- PHAT N/A
- EPS Growth
- GHRS N/A
- PHAT N/A
- EPS
- GHRS N/A
- PHAT N/A
- Revenue
- GHRS N/A
- PHAT $114,039,000.00
- Revenue This Year
- GHRS N/A
- PHAT $207.52
- Revenue Next Year
- GHRS N/A
- PHAT $96.46
- P/E Ratio
- GHRS N/A
- PHAT N/A
- Revenue Growth
- GHRS N/A
- PHAT 1049.82
- 52 Week Low
- GHRS $6.00
- PHAT $2.21
- 52 Week High
- GHRS $20.50
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- GHRS 34.28
- PHAT 56.48
- Support Level
- GHRS $13.71
- PHAT $11.89
- Resistance Level
- GHRS $14.59
- PHAT $13.00
- Average True Range (ATR)
- GHRS 0.76
- PHAT 0.72
- MACD
- GHRS -0.12
- PHAT -0.10
- Stochastic Oscillator
- GHRS 3.99
- PHAT 33.71
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.